You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,998,926


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,998,926
Title:Dimerized T-cell receptor fragment, its compositions and use
Abstract: Dimers of a peptide from the T-cell receptor (Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr) (SEQ ID NO:1) are disclosed for preventing the progression to AIDS in an animal model. Methods for delaying the progression to AIDS and restoring normal immunological responses in an animal model following infection are shown and comprise administering through various systemic routes dimeric T-cell receptor peptide V.beta. CDR1 to restore normal levels of Th1 cytokines interleukin 2 and interferon-.gamma., which are suppressed following infection, and those of Th2 derived cytokines interleukin 5, interleukin 6, interleukin 10, and immunoglobulin G, which are stimulated following infection.
Inventor(s): Marchalonis; John Jacob (Tucson, AZ), Watson; Ronald Ross (Tucson, AZ)
Assignee: The Arizona Boad of Regents on Behfl of the University of Arizona (Tucson, AZ)
Application Number:10/478,194
Patent Claims:1. A dimer comprising a monomer that (a) consists of, from the N-terminus to the C-terminus direction, the sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1) with the proviso that, if the sequences are present as an aqueous solution, then at least 81% of the occurrences of the sequence are present as a dimer; or (b) is a homolog of the .beta.3 peptide of the T-cell receptor .beta. chain clone YT35, the said .beta.3 peptide consisting of, from the N-terminus to the C-terminus direction, the sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), wherein the homolog has the sequence of a segment of another distinct human V.beta. gene which segment corresponds to the same segment as the said .beta.3 peptide and wherein the homolog has the sequence Cys-[X]-Trp-[Y], wherein [X] is a 10 or 11 amino acid sequence and wherein [Y] is a 4 amino acid sequence; or (c) is a variant of the monomer of (a) or (b), wherein: (i) the variant has the sequence Cys-[X]-Trp-[Y], wherein [X] is a 10 or 11 amino acid sequence that has the sequence of amino acids 2-11 of the .beta.3 peptide of the T-cell receptor .beta. chain clone YT35, which is Lys Pro Ile Ser Gly His Asn Ser Leu Phe, or the sequence of the same segment of another distinct human V.beta. gene which segment corresponds to the same segment as the said .beta.3 peptide; and (ii) wherein [Y] is a 4 amino acid sequence that has the sequence of amino acids 13-16 of the .beta.3 peptide of the T-cell receptor .beta. chain clone YT35, which is Tyr Arg Gln Thr, or the sequence of the same segment of another distinct human V.beta. gene which segment corresponds to the same segment as the said .beta.3 peptide, except that, at one position in total within the [X] and [Y] sequences, there is a substitution wherein the dimer when administered as a dose of 200 .mu.g/mouse to a C57BL/6 mouse infected with the LP-BM5 retrovirus, has the ability to normalize IL-4 secretion by mitogen-stimulated splenocytes of said mouse relative to a C57BL/6 mouse infected with the LP-BM5 retrovirus and treated with saline.

2. The dimer of claim 1 that is a homodimer.

3. A homodimer according to claim 2, wherein each monomer of the homodimer consists of, from the N-terminus to the C-terminus direction, the sequence Cys Ser Pro Lys Ser Gly His Asp Thr Val Ser Trp Tyr Gln Gln Ala (SEQ ID NO:2).

4. A dimer according to claim 1 with the proviso that, if the sequences are present as an aqueous solution, then at least 81% of the occurrences of the sequences are present as a dimer.

5. A pharmaceutical formulation comprising a dimer according to claim 1 and a pharmaceutically acceptable excipient.

6. A method for treating an infectious disease caused by an immunodeficiency-type retrovirus, the method comprising administering a composition comprising a dimer of claim 1 to an animal in need of treatment.

7. The method of claim 6 wherein the immunodeficiency-type retrovirus is a C-type retrovirus or a lentivirus.

8. The method of claim 7 wherein the lentivirus is HIV-1, HIV-2, HIV-3, simian immunodeficiency virus (SIV), or feline immunodeficiency virus (FIV).

9. A pharmaceutical formulation comprising a dimer of claim 1 wherein at least 82%, 83%, 84%, 85%, 88%, 90%, 92%, 95%, 98%, 99%, 99.5%, 99.9%, 99.99%, 99.999% or substantially 100% of the occurrences of the sequences are present as a dimer.

10. A composition comprising a dimer of claim 1 and a further therapeutic agent.

11. The composition of claim 10 wherein the further therapeutic agent is a peptide or an immune-stimulating adjuvant.

12. The composition of claim 10 wherein the further therapeutic agent is useful in the treatment of HIV-infection.

13. The composition of claim 10 wherein the further therapeutic agent is an antibiotic or an anti-histamine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.